Try our Advanced Search for more refined results
Life Sciences - May, 2015
311 articles
- Namenda Product-Hopping Ruling Opens Door To More Claims
- Namenda Isn't End Of NY AG's Pharma Work: Antitrust Chief
- 21 Investigations Added To HHS Oversight Agenda
- Ex-Merck Director's Pregnancy Bias Suit Heads To Jury
- Brand Battles: Bayer, Lego, Coca-Cola
- 4 IPOs Eye $552M To Start June After Brief Slowdown
- FDA Asked To Add HIV Warning To Birth Control Label
- New Wash. Law Invites Tribes Mulling Marijuana Biz
- 4 In-House Preferences For Better Outside Counsel
- FDA Botched Amarin's Vascepa Exclusivity, Judge Rules
- FTC Sues To Block $1.9B Steris-Synergy Merger
- Pa. Judge Urged To Keep 1st Pelvic Mesh Cases In Philly
- Shining A Light On Conn.'s Version Of The Sunshine Act
- Bio-Rad's Ex-GC Sues Over Firing Amid Bribery Investigation
- Pay-For-Delay Questions Linger After $1.2B Cephalon Deal
- 2nd Circ. Says Coercion Key To Namenda Injunction Ruling
- FTC's $1.2B Win Shows Pay-For-Delay Deals On Thin Ice
- No More Delays, Plaintiffs In Shire Pay-For-Delay Suit Told
- Daiichi Sankyo Looks To Fuse NJ Benicar Suits
- Paying The Price For Pay-For-Delay: Cephalon's 7-Year Saga
- Blue Cross Sued For Denying Gilead Hep C Drug Coverage
- Nautilus Asks Full Fed. Circ. To Review Indefiniteness Case
- Allergan Shakes Shareholders' Off-Label Botox Case
- Ruling Clears Way For Medical Cannabis In Florida
- FTC Health Care Chief: $1.2B Cephalon Deal A Strong Warning
- Analyzing Data Trends To Shape Complex Litigation Strategy
- Medtronic Wins Fees In Long-Running Mirowski Patent Case
- Boston Scientific Hit With Record $100M Verdict In Mesh Case
- Cancer Biotech MultiVir Pulls Plug On IPO Plans
- Internal Microbe Ecology Biotech Seres Eyes $100M IPO
- 7th Circ. Weighs Copyright Suit Over Amylin Drug Promos
- IP Firm Dodges Sanctions In Medical Device Co.'s Suit
- PE Firm Cinven To Buy France's Labco In $1.3B Deal
- Persuasive Experts At Trial: 3 Times A Charm
- Cephalon To Pay $1.2B To End FTC Pay-For-Delay Suit
- Acorda Hits Back At Hedge Fund Manager In PTAB Challenge
- FDA Beats Otsuka Suit Over Abilify Generics
- AbbVie Buys Back $5B Stock As Pharmacyclics Deal Sealed
- 2 VC-Backed Medical Device Cos. Aim For $147M In IPOs
- Pfizer Says Zoloft Birth Defect Suit Can't Wait For Science
- NJ Justices Won't Hear Dispute Over Generic Drug Settlement
- Ex-Bryan Cave Client Can't Escape $1.5M Fee Row
- And Now A Word From The Panel: The MDL Lexicon
- Philly Risperdal Trial Settles On Day Of Opening Arguments
- Allergan Can't Duck Eye Doctors' FCA Kickbacks Suit
- FDA Biosimilar Policy: More Questions, More Answers
- A New Compliance Challenge For Cos. Doing Business In UK
- NJ Appeals Court Boots Pharma Ad Exec's GoDaddy Suit
- 5 FCA Takeaways From High Court's KBR Ruling
- 9th Circ. Denies En Banc Rehearing For Amgen ERISA Suit
- High Court Won't Hear PhRMA's Appeal Of Drug Cleanup Law
- Causation Key For J&J In Philly Risperdal Fight
- Medicare Fraudster Gets 7 Years For $3.3M Scam
- Merck Offers EU Antitrust Fixes On $17B Sigma-Aldrich Buy
- Law360 Looking For IP Experts For New Series
- 2nd Circ. Asks How Expert Report Could Derail Pfizer Action
- Mass. Suit Over Zogenix Painkiller Restrictions Paused
- Bayer, Merck Hit In Pa. Court Over Avelox Nerve Damage
- Bolder Cures Act Could Ease Limits On Drug Cost Claims
- Amarin Seeks Injunction Blocking FDA's Off-Label Muzzle
- Pfizer MDL Plaintiffs Blast Bernstein Liebhard's Fee Bid
- Insurance Risks Surrounding Legal Cannabis
- 5 Insights From CBRE General Counsel Laurence Midler
- Mylan Says Kirkland 'Thumbs Its Nose' At Client Loyalty
- Philly Zoloft Trial Can Shape Expert Testimony In MDL
- Hagens Berman In Hot Seat Over Dropped GSK Suits
- 6th Circ. Upholds GE's Win In Omniscan Suit
- Natrol Gets Nod For Ch. 11 Plan Over IRS Opposition
- Hedge Fund Hits 'Ridiculous' Horizon Patent With AIA Review
- WilmerHale Guides Custom Joint Co. On $173M IPO Plan
- Medtronic Fights IRS Over Sealed Docs In $561M Tax Row
- Taxation With Representation: Sullivan, Ropes & Gray
- Actavis Faces Patent Suit Over Generic Opioid
- 2nd Circ. Says Actavis Can't Pull Old Namenda
- Calif. Justices Urged To Reconsider Pay-For-Delay Ruling
- FDA Adjusts Blood Donation Rules To Test For More Diseases
- AstraZeneca Loses Bid To Nix $42M Award In UK Generic Row
- Kirkland Says Work For Mylan Units Can't Trigger Conflict
- USPTO Joins Bayer's 'Flanax' Foreign Trademark Case
- Watson, Not Par, Infringed Novartis Dementia Patch: Fed. Circ.
- SAC Tipster Dropped From Investor Class Action
- 4 Issues To Watch As 21st Century Cures Act Advances
- Judge OKs Unlimited Damages For Tylenol Liver Bellwether
- Plaintiffs Gain Some Docs In Adderall Suit, May Get Others
- Novartis Catches Flak For Clawback Bid In FCA Kickback Row
- A Route To Directors' Early Exit From Merger Litigation
- Astellas Gets OK For $98M Deal In Prograf Antitrust MDL
- LifeCell Wins Duty-To-Warn Ruling In NJ AlloDerm Litigation
- Grassley Says Patent Troll Bill Will Tackle AIA 'Abuse'
- Sullivan & Cromwell Guides CVS In $12.7B Deal For Omnicare
- House OKs R&D Tax Credit, $33B In Research Funds
- Cooley Guides Adamas Pharma On $150M Follow-On
- Hernia Mesh Maker Wins Injunction In Trade Secrets Fight
- Knobbe Atty's Misconduct Doesn't Kill $467M Masimo Verdict, Judge Says
- VC Firm Raises $215M For University-Research Startup Fund
- Debt, Equity Markets Heat Up As Pharma M&A Soars
- FTC's Abbvie Loss Doesn't Apply To Actos Case, Court Told
- Janssen Scores FDA Approval For New Schizophrenia Drug
- Congress Could Be Coming For Dietary Supplements Soon
- Hagens Berman Objections To GSK Settlement Probe Rebuffed
- Pfizer Urges Zoloft MDL Judge To Block Plaintiffs' New Expert
- 2015 Law360 Minority Report
- The 50 Best Firms For Minority Partners
- Diversity Gap A Growing Threat To BigLaw Bottom Lines
- The 100 Best Law Firms For Minority Attorneys
- NuVasive Can't Nix Jury's $2.6M Fraud Verdict On Appeal
- Drunken Drivers Urge Justices To Hear Faulty BAC Test Suit
- J&J Will Pay $7.8M To Exit Ark. Risperdal Marketing Suit
- NECC's Ch. 11 Plan With $200M Meningitis Payouts Approved
- Robbins Geller $94M Fee In Pfizer Suit Too High, Judge Told
- Shire Investors Say AbbVie Can't Ax Suit Over Failed Inversion
- ITC To Investigate Hemophilia Drug Imports
- Pa. Firms See Green, But Want Ethics Rules For Medical Pot
- Lobbying The EU: New Requirements For A 'Voluntary' Regime
- New Medicaid Bill Targets Soaring Generic-Drug Prices
- Phony Docs Torpedo $25M Verdict In Trade Secret Row
- Cardiovascular Biotech Celyad Targets $115M In US IPO
- Ex-Sanofi Worker Files Class Action Over Stock Drop
- Man Accused Of Smear Campaign To Short Stock Skips Court
- Last Pa. Reglan Preemption Challenge Denied By High Court
- High Court Won't Bite On Fixodent MDL Evidence Claim
- Olympus Sued In Pa. Over FDA-Flagged Uterine Surgery Tool
- Sweet Home No More, Innovator Liability Leaves Alabama
- Consider 5 Things Before Choosing An E-Discovery Provider
- Skadden Guides Endo In $8B Deal For Generics Co. Par Pharma
- Citibank Appeals Denial Of Standing In Natrol Ch. 11
- Stryker Gets $9M In TIG Insurance Knee Replacement Deal
- 23andMe Gets Some Insurer Claims Paused In DNA Test Row
- Sensa Hits Doc With Contract Suit After $26M FTC Accord
- Another NJ Doc Sentenced In $100M Blood Lab Bribe Scheme
- Full 10th Circ. Won't Rehear Medtronic Infuse Injury Suit
- Pepper Hamilton Adds Ex-Norton Rose Fulbright M&A Pro
- Mylan To Appeal Dismissal Of Doryx Product-Hopping Suit
- Covidien Accused Of Firing Salesman For Reporting Kickbacks
- Circassia Plunks Down $376M For 2 Asthma Treatment Cos.
- Darvocet Warning Suits Should Go Back To Calif., Judge Says
- FDA Warns Of Diabetes Drugs From AstraZeneca, Janssen
- GSK Files New Suit Against Teva Over Generic Wellbutrin
- EQT's $621M IPO Nabs Spotlight Amid Rough Week For Debuts
- Agriculture Biotech Arcadia Raises $61.5M In Slashed IPO
- Genomic Profiling Is Double-Edged Sword In Drug Litigation
- Del. High Court Opens Exit Door For Directors In Buyout Suits
- Class Actions Are Biggest Worry For US GCs
- CVS Ducks Contract Case After Pharmacy Drops Claims
- 10th Circ. Calls Timeout On Utah Contact Lens Pricing Law
- GCs Rightly Fear The Regulators
- Five Prime Targets $200M In Follow-On Offering
- FedEx Can't Duck Criminal Case Over Drug Shipments
- Agriculture Biotech Co. Arcadia Trims IPO Expectations
- 3 VC-Backed Biotechs Join Flurry Of Anticipated IPOs
- Galapagos Scores $275M As IPO Beats Sweetened Terms
- As TPP Deal Looms, Pols Double-Dig In On Drug Patents
- Parsing Pros And Cons Of FDA's Expedited Access Pathway
- Court-Appointed Experts — A Powerful But Rarely Used Tool
- Merck Nabs Partial Win In Vioxx Securities Fraud Row
- Takeda Says FTC's AbbVie Loss Backs Actos Dismissal Bid
- Glaukos Eyes IPO As Life Sciences Hit Rough Patch
- Masimo Won't Face Charges Over Blood-Testing Devices
- FDA Shows How Patient Opinions Support Device Approvals
- Fed. Circ. Vacates Elan's Win In Classen Patent Suit
- Sandoz Wants Amgen To Post $180M Bond For Losses
- Bankruptcy Judge Greenlights SIGA Insider Trading Probe
- GSK Urges Dismissal Of Hagens Berman Thalidomide Suits
- House Panel Rolls Out Latest '21st Century Cures' Bill
- Siemens To Pay $6M To End Gov't Overcharging Investigation
- Boston Scientific Finances Endo Deal With $1.85B Debt Sale
- Nestle Health Science Says Competitor's Generic Is Fake
- E-Cigarette Class Actions Could Be On Fire Someday
- Takeaways From FTC Settlement With Cardinal Health
- Shearman & Sterling Advises Pall In $13.8B Sale To Danaher
- Fla. Judge Nixes Bond For Convicted Stock Scheme Atty
- Kirkland's Past With Mylan Rivals May Boost Conflict Defense
- Hagens Berman Fights Thalidomide Plaintiff 'Interrogations'
- FDA Unveils New Biosimilars Q&A
- Baxter Expands Cancer Therapies With $900M Oncaspar Buy
- 4 Issues To Watch In Amarin's Off-Label Marketing Suit
- Biotech Firm Galapagos NV Pegs Rosier $250M IPO Goal
- Ranbaxy Accused Of Filing Deceptive Drug Applications
- Hospira, Par Pharma Settle Epinephrine False Ad Suit
- Giant Eagle Hits AbbVie With AndroGel Pay-For-Delay Suit
- J&J Cleared Of RICO Charges Over Risperdal Side Effects
- Allergan Consumers Want Class Status In Skin Cream Suit
- FTC Hits Weight Loss Supplement Maker With False Ad Suit
- Key Considerations For Investing In Marijuana Companies
- Sheppard Mullin Boosts IP Group With Ex-Kilpatrick Patent Pro
- Pfizer, Wyeth Sued After Advil 'Melts' Girl's Skin Off
- FDA Biosimilar Policy: 3 Documents, 1 Key Theme
- Yanking Namenda IR Would Cost Medicare $6B, 2nd Circ. Told
- Contact Lens Makers Can't Delay Utah Pricing Agreement Law
- Whistleblowers Decry Allergan's FCA Immunity Bid
- Novartis Prevails In Liability Suit Over Aredia
- Cherokee Suit Against Takeda Transferred To Actos MDL
- AbbVie Not Allowed To See FTC Docs In Pay-For-Delay Suit
- Accutane Ruling Blocking Expert Testimony Kills 2K Suits
- Endo Slams Walgreens' Lidoderm Pay-For-Delay Suit
- Endo Settles 100 Vaginal Mesh Suits
- J&J Plans Appeal Of $3M Award In Topamax Birth Defects Suit
- Wash. Gov. Signs Law To Allow Tribal-State Marijuana Pacts
- Teva, Others Dodge Chicago's Suit Over Painkiller Marketing
- Ethicon Surgical Stapler Suit Belongs In Germany, Judge Says
- Teva's Effect On Review Of PTAB Claim Construction Rulings
- Bankrupt Siga Blasts Creditors' Investigation Bid
- Amarin Says Off-Label Marketing Rules Flout 1st Amendment
- Calif. High Court Fleshes Out Pay-For-Delay Test In Cipro
- Natrol Judge Delays Ch. 11 Plan Confirmation
- Tallgrass' $1.2B IPO Nabs Spotlight As 4 Biotechs Postpone
- Vitamin Shoppe Pulls Untested, Amphetaminelike Ingredient
- Calif. High Court's Cipro Ruling Is A Relief For Pharma Cos.
- Week's 9 IPOs Set To Test Investors' Thinning Risk Appetite
- 3rd Circ. Says ERISA Allows 'Catalyst Theory' Fees
- Heart Device Co. Wants Opposing Counsel DQ'd In IP Dispute
- Pfizer MDL's $91M Atty Fees Misallocated, Firm Says
- 1st Circ. Strengthens Preemption For Brand-Name Drug Cos.
- Grunenthal, Sanofi Must Wait For Thalidomide Suit To Play Out
- Bernstein Litowitz To Co-Lead Allergan Investor Suit
- Liberty Medical Gets Nod For Ch. 11 Disclosure Statement
- Collegium Prices $70M IPO As Another Biotech Postpones
- Fed. Circ. Rules Only It Can Hear AIA Interference Appeals
- Rite Aid Joins Pay-For-Delay MDL Over Generic Niaspan
- Fed. Circ. Affirms Invalidity Of AstraZeneca Inhaler Patent
- Give Brand Biologics, Biosimilars Same Naming Rules: Sandoz
- Foreign Medical Cos. Cop To $33M Drug Smuggling Scheme
- 5 Must-Know Facts For Companies Blowing The FCA Whistle
- BASF Sells 3 Drug Ingredients Plants To Siegfried For $304M
- Forest City Lobs $731M Offering To Back MIT Portfolio Buy
- FDA Recalls Maquet Heart Device Over Death, Injury Reports
- FDA Mostly Improving Generic-Drug Inspections, Report Finds
- Sandoz Says Allergan Glaucoma Patents Adds 'Nothing New'
- J&J, NYU Med School To Create 'Compassionate Use' Panel
- Calif. High Court OKs Pay-For-Delay Challenges
- Clearing The Smoke Surrounding Policy On Marijuana Apps
- Feds Intervene Against Novartis After Co-Defendant Settles
- Patient Says Intuitive Surgical's Robot Causes Severe Injuries
- 3-D Printing Of Medical Devices Has Many Dimensions
- Ala. Generics Injury Ruling May Still Sway Other States
- Robbins Geller Seeks $94M Fees In $400M Pfizer Class Deal
- Del. High Court Asked To Let Directors Out Of Buyout Suits
- Judge Trims FTC's Pay-For-Delay Suit Against AbbVie
- Fed. Circ. OKs Hikma Gout Drug Sales In Takeda IP Case
- Two Doctors Sentenced In Medical Lab Bribery Scheme
- Dead Soldier's Parents Say GNC Can't Slip 'Jack3d' Suit
- Teva Says Antitrust OK Just Months Away For $43B Mylan Deal
- Health Care Recruiter Sues Ex-Employee For Stealing Secrets
- Endoscope Maker EndoChoice Plans $115M IPO
- Fish Grows IP Practice With Hughes Hubbard Pharma Pro
- Cooley Leads HTG In Week's 2nd Diagnostics IPO
- Prosensa Beats IPO Investors' Suit Over Failed Drug
- Amgen Wins Delay Of Sandoz Biosimilar At Fed. Circ.
- Cancer Biotech Adaptimmune Files $191M IPO
- Pillsbury Adds Ex-Baker Botts Tech Partner To Austin Office
- Alexion To Buy Synageva For $8.4B In Latest Big Pharma Deal
- Scrapping Drug Price Controls, China Vows Market Vigilance
- Corporate Perspectives On Cybersecurity: A Survey Of Execs
- Teva And The Dictionary: A Status On The Standard Of Review
- Wachtell Guides AbbVie In $16.7B Bond Offering
- Boston Scientific Didn't Test Pelvic Mesh, Jury Told
- Veteran Pharma GC Says Startup Gig Flexes Legal Muscles
- Mylan's Kirkland Suit May Hold Clues For Conflict Waivers
- Biotronik Wants Insurers' $28M Pacemaker Verdict Suit Axed
- 11th Circ. Flips Contempt Order Against Hi-Tech Execs
- Pa. Federal Court Picks Trial Suits In Zoloft Birth Defect MDL
- Allergan Heirs Accuse McDermott Of Elder Abuse, Malpractice
- 500 Groups Urge Congress To Nix ACA Cost-Control Board
- Citibank Denied Bid To Delay Natrol Ch. 11 Plan Confirmation
- Dozens Of State Law Claims Sliced From Lidoderm MDL
- Allergan Counterclaims Stand In $600M Botox Royalty Row
- Honigman Boosts Mich. Practice With 2 PE, Securities Pros
- Drug Return Co. Worker Pleads Guilty In $116M Diversion Plot
- Bayer Can't Ship Reinstated Whistleblower 500 Miles Away
- Migraine Drug Developer CoLucid Slashes IPO Target
- Olavi Dunne Adds 2 Ex-Russ August Attys To Head LA Office
- Takeda's $2.4B Actos Deal Ends 5th Circ. Appeal
- Cubist Tells Fed. Circ. MRSA Drug Patents Are Valid
- An In-Depth Look At The Personal Care Products Safety Act
- B&L Sues To Stop Production Of Generic Eyedrops
- WilmerHale Leads Epizyme In $250M Follow-On Offering Plans
- DaVita To Pay Record $495M To Settle Kidney Drug FCA Suit
- Kirkland Takes Mylan's Teva Conflict Suit To Federal Court
- Heart Risk Claims Still Dog Pfizer Testosterone Drug
- Bayer Wants Out Of One-A-Day Labeling Class Action
- Lincare Says 'Arcane' FCA Suit Based on Unknowable Regs
- Justices Won't Review Invalidation Of Bristol-Myers Patent
- FDA Tries To Clear Path To Pediatric Device Approvals
- 1 Law Firm Dominates April IPO Activity
- AstraZeneca Urges Fed. Circ. To Find Asthma Inhaler IP Valid
- FTC Gets Restraining Order Against 'Bogus' Diet Pills Co.
- J&J, Ethicon Lose Bid To Toss $5.7M Pelvic Mesh Verdict
- Teva's FDA Testing Violates Lovenox Patent, Fed. Circ. Told
- Lupin Smacked With IP Suit Over Generic Paxil
- IRS Balks At Natrol Liquidation Plan Over 11th-Hour Deal
- Patterson Cos. To Pay $1B For Animal Health International
- Mylan Sues Kirkland & Ellis Over Teva Takeover Bid
- Accredo To Pay $60M In Novartis Exjade Kickback Suit
- Ala. Undoes Brand Drug Liability For Generic Injury
- IPO Activity Set To Spring Back As 14 Cos. Target $2B
- Sens. Ask FTC To Probe Supplements With Untested Ingredient
- Tygacil Injury Suit Against Pfizer Trimmed
- Brand Battles: Sears, Red Bull, Novartis
- Feds Attack Natrol's Ch. 11 Plan For Favoring Equity
- Thermo Fisher Tells Fed. Circ. Not To Mull $61M Verdict Toss
- Texas High Court Won't Hear Fen-Phen Referral Fee Fight
- Eli Lilly Rips Expert For 'Unreliable' Cymbalta Testimony
- Week's 4 IPOs Draw $795M As Market Revs Up For May Surge
- New Health Frauds Abound In Big Calif. District, DOJ Attys Say
- Apotex Seeks 1st-Ever High Court Inequitable Conduct Review
- Antitrust Suit Over Allergan Pink-Eye Meds Heads For Trial
- Omnicare Wants To Boot One Relator From FCA Kickback Suit
- USPTO Tells 4th Circ. Bayer Has Standing In 'Flanax' TM Row
- Stryker Resolves Unintended Bone Growth Suit
- Investor Wants Gordon Rees Booted From Securities Suit
- The Language Of The DQSA Contradicts Congressional Intent